29
Participants
Start Date
October 7, 2021
Primary Completion Date
February 27, 2023
Study Completion Date
February 27, 2023
ITIL-168
ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
St. Luke's University Health Network, Bethlehem
Fox Chase Cancer Center, Philadelphia
Georgetown University Medical Center, Washington D.C.
Orlando Health Cancer Institute, Orlando
The University of Miami - Sylvester Comprehensive Cancer Center, Miami
Moffitt Cancer Center, Tampa
University of Louisville, James Graham Brown Cancer Center, Louisville
Cleveland Clinic - Taussig Cancer Center, Cleveland
University of Minnesota, Masonic Cancer Center, Minneapolis
Loyola University Chicago, Maywood
Rush University Cancer Center, Chicago
University of Colorado - Anschutz Cancer Pavilion, Aurora
The Angeles Clinic and Research Institute, Los Angeles
USC - Norris Comprehensive Cancer Center, Los Angeles
UCLA Health - Westwood Cancer Care, Los Angeles
University of California San Diego, Moores Cancer Center, La Jolla
Stanford Cancer Institute, Stanford
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Atlantic Health System - Morristown Medical Center, Morristown
Princess Margaret Cancer Centre, Toronto
Cambridge University Hospital NHS Foundation Trust - Addenbrooke's Hospital, Cambridge
Lead Sponsor
Instil Bio
INDUSTRY